Member Info for beinthelead

There will be undoubted connection between some of those, yes. Likely why he got booted out! He made mess of most things.

We know that cleavage is done in the TME. The moa for the toxicities? Couldn’t care less. They present.

Sub-trial? Nah, it’s a Dx aid.

You simply believe it or you don’t.

Thorn - the trial has taken too long. They wasted a shed load of cash. They have had awful management. Bang on about this and I’ll be right behind you.

This active FAP nonsense is just that. Nonsense.

*bloke

To bring back another line from CC; they have validated that the cleavage is activated by ‘active FAP’ in them TME, not the stuff in those arthritic joints you know so much about.

It also cures a blood that has (had!) stage 4 cancer.

An update on Q2 dosing is all that matters.

He’s not. He’s clearly a very bright bloke that’s working toward changing a field of medical engineering. Doing great work.

The Affimer is a dud in this business. As in, will never be a commercial success. Divorce the two.

Never in a million years is it going to happen. Part of the reason AS left. Affimer is a dud.

Hiding in plain sight 😶‍🌫️

Aldebaran - you do remember when you were trolling Avacta for months on end? Here and your now deleted Twitter?? Ala TW?

Telegram is nuts by the way. Why you’d want to join a group that promotes rumour is anyone guess.

What was the handshake, Ice?

If it further shows how FAP impacts the effectiveness of the drug during this P1 trial, that would be a good thing.

Plonker.

Exactly. They’ve had the head in the sand for long enough.

What about the preceding fortnight? This isn’t just macros. It’s the market bored of waiting in a volatile stock. Just get on with it Avacta.

Thanks JT/Thompi. So they are calc’ing it based on the ratio vs known dox distribution? Quite liberal actually. Suppose it’s as good as they could achieve.

How are quantifying lifetime exposure to dox, JT?

What if there’s a DLT in C3?

Of course it is. It didn’t protect the LFT Omicron debacle. Two weeks after RNSing it detected it, to a failure. They’ll report when they like.

100%

While this cesspit argues with itself, Avacta are 3 years deep into a P1 study - I think all can agree they need to /should sign a deal.

Enjoy your time PL.

I like your optimism, ie you can instill some patience into an infested board like this. It won’t happen. Most folks are checking the SP 50x/day. Those 10% days are like crack.

The mindless ramping is all rubbish. No substance and changes like the wind.

I do think a deal is struck far sooner than P2. In some ways it has to be, or partner an asset to fund P2. It costs a fortune compared to what we’ve spent to date. They just cannot dilute by that much. Especially when throwing cash at the CLN. As always with Avacta TIME will tell.

Got to disagree Ice. There’s multiple preclinical deals being struck before a needle has entered an arm. For billions.

I agree on the mental ramping and numbers, but you a kicking this a bit too far.

Indeed the board is a mess. Haven’t looked in for a while. Same posters fluffing each other, can’t blame Wyn entirely. Which is mental given it’s a the biggest wind up going.

Shut it down. It’s the summer.